[1] ANTONIA S J, VILLEGAS A, DANIEL D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer [J].N Engl J Med, 2017, 377(20): 1919-1929.
[2] SPIGEL D R, FAIVRE-FINN C, GRAY J E, et al. Five-year survival outcomes from the PACIFIC Trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer[J]. J Clin Oncol, 2022, 40(12): 1301-1311.
[3] ZHOU Q, CHEN M, WU G, et al. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable(stage III) non-small cell lung cancer(NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy[J]. Transl Lung Cancer Res, 2020, 9(5): 2008-2015.
[4] OH W K. COVID-19 infection in cancer patients: early observations and unanswered questions[J]. Ann Oncol, 2020, 31(7): 838-839.
[5] LIANG W, GUAN W, CHEN R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China[J]. Lancet Oncol, 2020, 21(3): 335-337.
[6] ZHANG L, ZHU F, XIE L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China[J]. Ann Oncol, 2020, 31(7): 894-901.
[7] GEISSLINGER F, VOLLMAR A M, BARTEL K. Cancer patients have a higher risk regarding COVID-19-and vice versa?[J]. Pharmaceuticals: Basel, 2020, 13(7): 143.
[8] WAN S, YI Q, FAN S, et al.Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus(COVID-19) infected patients[J]. Br J Haematol, 2020, 189(3): 428-437.
[9] QIN C, ZHOU L, HU Z, et al. Dysregulation of immune response in patients with Coronavirus 2019(COVID-19) in Wuhan, China[J]. Clin Infect Dis, 2020, 71(15): 762-768.
[10] TAN M, LIU Y, ZHOU R, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China[J]. Immunology, 2020, 160(3): 261-268.
[11] ROSE-JOHN S. Blocking only the bad side of IL-6 in inflammation and cancer[J]. Cytokine, 2021, 148: 155690.
[12] HASANVAND A. COVID-19 and the role of cytokines in this disease[J]. Inflammopharmacology, 2022, 30(3): 789-798.
[13] ZHU M, LI X, CHENG X, et al. Association of the tissue infiltrated and peripheral blood immune cell subsets with response to radiotherapy for rectal cancer[J]. BMC Med Genomics, 2022, 15(Suppl 2): 107.
[14] BAYLISS R, CHOI J, FENNELL D A, et al. Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs[J]. Cell Mol Life Sci, 2016, 73(6): 1209-1224.
[15] SAMPSON J, RICHARDS M W, CHOI J, et al. Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation[J]. EMBO Rep, 2021, 22(12): e53693.
[16] YANG L, LI G, ZHAO L, et al. Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer[J]. Tumour Biol, 2014, 35(10): 9759-9767.
[17] TAKEZAWA K, OKAMOTO I, NISHIO K, et al. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer[J]. Clin Cancer Res, 2011, 17(8): 2140-2148.
[18] DUCRAY S P, NATARAJAN K, GARLAND G D, et al. The transcriptional roles of ALK fusion proteins in tumorigenesis[J]. Cancers: Basel, 2019, 11(8): 1074.
[19] MAUS M K, STEPHENS C, ZEGER G, et al. Identification of novel variant of EML4-ALK fusion gene in NSCLC: potential benefits of the RT-PCR Method[J]. Int J Biomed Sci, 2012, 8(1): 1-6.
[20] LI T, MAUS M K, DESAI S J, et al. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays[J]. J Thorac Oncol, 2014, 9(1): 18-25.
[21] ZHANG S S, NAGASAKA M, ZHU V W, et al. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive(ALK+) NSCLC[J]. Lung Cancer, 2021, 158: 126-136. |
